Corvus Forms $106 Million China Subsidiary with China Rights to Four of its Assets
publication date: Oct 5, 2020
Corvus Pharma formed a China subsidiary, Angel Pharma, to develop its three clinical stage assets and one preclinical platform in China. Angel will have a post-money value of $106 million. Corus will own 49.7% of Angel, while three China biopharma investors will invest $41 million for the rest. The investors are Tigermed-Betta Pharma, Hisun Pharma and Zhejiang Puissance Capital. Angel will have China rights to three Corvus clinical-stage candidates – ciforadenant, CPI-006 and CPI-818 – and global rights to Corvus’ BTK inhibitor preclinical programs. More details....
Stock Symbol: (NSDQ: CRVS)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.